Forma Therapeutics Holdings Inc. Stock News

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer

Forma Therapeutics Holdings Inc (NASDAQ: FMTX) announced new data from its ongoing Phase 1 trial of etavopivat (FT-4202) in sickle cell disease. Data were presented at the Annual European Hematolog

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced new dat

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Present Data from Pivotal Phase 2 Trial of Olutasidenib at ASCO 2021

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Participate in Upcoming Investor Conferences

Forma Therapeutics Holdings, Inc. (FMTX) CEO Frank Lee on Q1 2021 Results - Earnings Call Transcript

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on May 14, 2021

Forma Therapeutics Holdings, Inc. (FMTX) CEO Frank Lee on Q4 2020 Results - Earnings Call Transcript

Forma Therapeutics Holdings Inc (NASDAQ: FMTX) has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202, a pyruvate kinase R activator. The 600 mg high-dose cohort

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics reports financial results from Q4 and full year 2020, as well as business updates.

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces positive data from the 600 mg cohort in the Phase 1 trial of FT-4202 in sickle cell patients.

Forma Therapeutics (FMTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics provides a review of 2020 company highlights and an outline of anticipated 2021 milestones.

WATERTOWN, Mass.--(BUSINESS WIRE)--Forma Therapeutics announces the closing of an underwritten public offering of 6,095,000 shares of its common stock.